Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality

Author(s):  Hagan John C III, Everett Eric, Chamberlain Tyler

Issue:  May/Jun 2020 - Volume 24, Number 3
View All Articles in Issue

Page(s):  194-197

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Page 1
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Page 2
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Page 3
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Page 4

Download in electronic PDF format for $75

Abstract:  Beta blockers (timolol 0.5% ophthalmic solution) delivered topically to the eyes or sublingually have recently been reported in case series and small placebo controlled studies to be effective in some cases of acute migraine. Rapid systemic absorption to achieve therapeutic levels of beta blockers is extremely important in the treatment of acute migraine. Nasal delivered beta blockers have been shown to be absorbed as fast as intravenous administration and seem ideal for acute migraine treatment. A nasal delivered beta-blocker spray has not been available. In 2019, O’Brien Pharmacy prepared a compounded timolol nasal spray that is now available to authorized prescribers. The theoretical basis for using nasal beta blocker spray is presented and research on fast-acting beta-blocker solutions for acute migraine is reviewed.

Related Keywords: John C. Hagan, III, MD, FACS, FAAO, Eric Everett, RPh, Tyler Chamberlain, PharmD, acute migraine, beta-blockers, beta-adrenergic antagonists, timolol eye drops, nasal spray, intranasal administration, formulation, Mucolox gel, beta blockade contraindications

Related Categories: FORMULATIONS, PAIN MANAGEMENT, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Choo Winnie
Jul/Aug 2017
Pg. 282-289

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Timolol 0.125%/Mucolox 15%/0.9% Normal Saline Nasal Spray
Allen Loyd V Jr
Mar/Apr 2023
Pg. 153

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

A Concise Discussion of Headache Types, Part 3: Migraine
Williams LaVonn A
, Allen Loyd V Jr
Jul/Aug 2012
Pg. 270-274

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Labetalol 50-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 233

Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2018
Pg. 233

Compounding with Beta-1, 3-D-Glucan
Keller Ted
Sep/Oct 2000
Pg. 342

Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
Jul/Aug 2018
Pg. 325

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Metoprolol Tartrate 1-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2013
Pg. 333

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Autologous Serum Eye Drops for Severe Dry Eye Syndrome in a Patient with Chronic Graft-vs-Host Disease: A Case Report
Mixon Bill
, Mixon Jan, Isbey Edward K III, Sprinkle Shari
Sep/Oct 2014
Pg. 370-377

Return to Top